A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins. The effectiveness of the therapy lies in its ability to

read more>>

SAN DIEGO - Mast Therapeutics, Inc., announced that two posters for its lead product candidate, MST-188, were presented at the 7th Annual Sickle Cell Disease Research & Educational Symposium, currently underway in MiamiBrian M. Culley, Chief Executive Officer, said: "Increasing evidence suggests t

read more>>

Trial Expands to Two Centers; Approval Includes Significant Increase in DosingROCKVILLE, Md., -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has received approval from the Food and Drug Administration (FDA) to commence a Phase II trial using NSI-566 spinal cord-derived human neural stem c

read more>>

Québec City, Canada – Aeterna Zentaris Inc. today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide

read more>>

Orphan Drug Designation Could Provide Financial Incentives and Faster Regulatory ReviewSEATTLE, April 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for OMS721

read more>>

SOUTH SAN FRANCISCO, Calif., April 16, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the U.S. Patent & Trademark Office (USPTO) has issued to Hyperion U.S. patent number 8,404,215 entitled, METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS. The

read more>>

LEIDEN, The Netherlands and SAN DIEGO, Calif. (April 17, 2013.) Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to obtain marketing approval for RUCONEST

read more>>

Expanded label approved in 23 European countries for treatment and pre-procedure prevention of acute episodes of hereditary angioedemaMARBURG, Germany, April 16, 2013 /PRNewswire/ -- CSL Behring today announced that European health authorities have approved an extended use of Berinert®, a C1-este

read more>>

Liestal, Switzerland, April 16, 2013 - Santhera Pharmaceuticals (SIX: SANN) announced today that the Phase III DELOS study of orally administered Catena® in patients with Duchenne Muscular Dystrophy (DMD) successfully passed a planned futility and safety analysis. The independent Data Safety "I a

read more>>

Eteplirsen Manufacturing and Clinical Activities Continue as PlannedCAMBRIDGE, MA -- (Marketwired) -- 04/15/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding a potential application for accelerated

read more>>